Avenue Therapeutics
menu
  • About
    • Management Team
    • Board of Directors
  • Pipeline
  • Publications
  • Investors
    • News & Events
      • Overview
      • Press Releases
      • IR Calendar
      • Email Alerts
    • Company Info
      • Overview
      • Management Team
      • Presentations
      • Contacts
      • FAQ
    • Financial Info
      • Overview
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Stock Data
      • Quote
      • Charts
      • Historical Data
    • SEC Filings
      • Overview
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Overview
      • Board of Directors
      • Board Committees
      • Governance Documents
  • Events
  • Contact Us
    • Careers
      • Email Alerts

Press Releases

Investors

Investors

  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Mar 08, 2023

Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates

Mar 02, 2023

Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy

Jan 31, 2023

Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement

Jan 27, 2023

Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules

Nov 10, 2022

Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Nov 08, 2022

Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders

Oct 11, 2022

Avenue Therapeutics Announces Closing of $12 Million Underwritten Public Offering

Oct 06, 2022

Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering

Sep 22, 2022

Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA

Feb 15, 2022

Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • Privacy
  • Disclaimer
  • Contact Us


twitter icon linked-in icon
Website Design, Maintenance and Hosting by Tidal Media Group
Copyright ©2023 Avenue Therapeutics.

logo